Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting Septembe...(income (loss) 4047 (18378)...),Health

Other income (expense), net (1,744) (641) 126 (831)

Equity in loss of joint venture (166) (121) (663) (534)

Net investment gain 3,190 - (583) 16,013

Interest income 2,919 1,506 8,974 5,343

Interest expense (1,712) (1,553) (6,781) (6,793)

Income from continuing

operations before provision

(benefit) for income taxes 6,534 (19,187) 8,795 6,095

Provision (benefit) for income

taxes 1,489 (8,491) 2,054 (5,726)

Income (loss) from continuing

operations 5,045 (10,696) 6,741 11,821

Discontinued operations:

Loss from discontinued operations - (1,548) - (4,957)

Loss from disposal - (38,018) - (38,018)

Benefit for income taxes - (14,549) - (15,845)

Loss from discontinued operations - (25,017) - (27,130)

Net income (loss) $5,045 $(35,713) $6,741 $(15,309)

Basic earnings (loss) per share

of common stock:

Income (loss) from continuing

operations $0.15 $(0.31) $0.20 $ 0.35

Loss from discontinued operations - (0.73) - (0.79)

Net income (loss) $0.15 $(1.04) $0.20 $(0.44)

Diluted earnings (loss) per

share of common stock:

Income (loss) from continuing

operations $0.15 $(0.31) $0.19 $ 0.35

Loss from discontinued

operations - (0.73) - (0.79)

Net income (loss) $0.15 $(1.04) $0.19 $(0.44)

Weighted average number of

'/>"/>